Pavel Raifeld, Innoviva CEO
Cash-strapped antibiotics player Entasis could go private with a small-dollar buyout offer on the table
It looks like antibiotics player Entasis may be getting off Nasdaq the same way it arrived — with a whimper.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
